Merck's M&A Focus Is On Early-Stage Deals: Licensing Exec
This article was originally published in The Pink Sheet Daily
Executive Summary
During a panel at the BIO CEO & Investor conference, Merck's chief licensing officer talks about early-stage opportunities and admits big pharma is becoming more "outwardly facing" when it comes to innovation.
You may also be interested in...
Merck/Schering: The Next Wave Of Consolidation
News of Pfizer's takeover of Wyeth has hardly had time to sink in and already a second mega-merger is shaking up big pharma. This time Merck is the buyer; the company announced March 9 that it proposes to acquire its cardiovascular joint venture partner Schering-Plough in a deal valued at $41.1 billion
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.